IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12821751.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The acute antidyskinetic effects of IV amantadine in HD were evaluated. A 2-hour IV infusion of amantadine or placebo was administered to nine patients with HD on two different days in a double-blind, randomized crossover fashion. All patients subsequently received oral amantadine unblinded for a 1-year period. A reduction of dyskinesia scores was reported during both IV and oral amantadine treatment (p < 0.05). No significant changes were observed in neuropsychological tests or psychiatric rating scales.
Medical subject headings
- Amantadine
- Excitatory Amino Acid Antagonists
- Huntington Disease